EIGR · Eiger Biopharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $3.21M | $4.64M | - | - | $4.02M | $4.09M | $2.67M | - | $3.04M |
| Cost of Revenue | - | $115.0K | - | $118.0K | - | $1.23M | $151.0K | $110.0K | - | $318.0K |
| Gross Profit | - | $3.09M | - | - | - | $2.79M | $3.94M | $2.56M | - | $2.72M |
| R&D | - | $14.57M | $19.40M | $16.75M | - | $22.20M | $16.99M | $17.57M | - | $18.11M |
| SG&A | - | $5.45M | $5.53M | $9.52M | - | $6.96M | $7.03M | $6.81M | - | $5.03M |
| Total Operating Expenses | - | $20.14M | $24.62M | $26.38M | - | $30.39M | $24.17M | $24.49M | - | $24.89M |
| D&A | - | - | - | $74.0K | - | - | - | $73.0K | - | - |
| Operating Income | - | ($16.93M) | ($19.98M) | ($22.26M) | - | ($26.37M) | ($20.08M) | ($21.82M) | - | ($21.85M) |
| Interest Expense | - | $1.41M | $1.34M | $1.28M | - | $1.09M | $934.0K | $886.0K | - | $894.0K |
| Income Tax | - | $0 | $2.0K | $2.0K | - | $0 | $17.0K | $9.0K | - | $16.0K |
| Net Income | - | ($18.03M) | ($20.70M) | ($22.78M) | - | ($27.11M) | ($21.88M) | ($22.64M) | - | ($22.22M) |
| EPS - Basic | - | ($0.41) | ($0.47) | ($0.52) | - | ($0.65) | ($0.51) | ($0.64) | - | - |
| EPS - Diluted | - | ($0.41) | ($0.47) | ($0.52) | - | ($0.62) | ($0.51) | ($0.64) | - | - |
Balance Sheet
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $25.44M | $27.50M | $22.98M | $15.18M | $25.80M | $26.31M | $36.57M | $46.56M | $22.22M | $49.26M |
| Accounts Receivable | $1.68M | $1.32M | $3.71M | $3.89M | $1.75M | $2.46M | $1.04M | $2.29M | $2.58M | $2.76M |
| Inventory | $1.56M | $1.10M | $1.10M | $5.34M | $2.85M | $2.82M | $2.88M | $1.91M | $2.61M | $2.62M |
| Accounts Payable | $2.12M | $4.86M | $4.95M | $11.86M | $8.97M | $10.50M | $9.95M | $9.22M | $7.76M | $6.75M |
| Current Assets | $37.84M | $54.62M | $70.48M | $96.91M | $117.53M | $142.29M | $157.70M | $147.36M | $103.36M | $99.09M |
| Total Assets | $38.83M | $55.65M | $72.36M | $99.23M | $120.14M | $143.74M | $163.69M | $153.33M | $126.40M | $140.28M |
| Current Liabilities | $53.28M | $16.52M | $16.71M | $24.00M | $25.12M | $26.12M | $21.85M | $36.61M | $29.90M | $22.01M |
| Long-term Debt | $0 | $40.73M | $40.35M | $39.99M | $39.63M | $39.31M | $38.92M | $19.45M | $23.99M | $28.52M |
| Total Liabilities | $53.28M | $57.26M | $57.06M | $63.99M | $64.83M | $65.44M | $60.77M | $56.06M | $54.00M | $50.81M |
| Stockholders' Equity | ($14.46M) | ($1.60M) | $15.29M | $35.24M | $55.31M | $78.31M | $102.92M | $97.27M | $72.40M | $89.47M |
| Retained Earnings | ($512.16M) | ($498.70M) | ($480.67M) | ($459.98M) | ($437.19M) | ($412.06M) | ($384.94M) | ($363.06M) | ($340.42M) | ($318.65M) |
Cash Flow
| Line item | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | ($24.00M) | - | - | - | ($18.46M) | - | - |
| Investing Cash Flow | - | - | - | $13.38M | - | - | - | ($3.00M) | - | - |
| Financing Cash Flow | - | - | - | $41.0K | - | - | - | $45.80M | - | - |
| CapEx | - | - | - | $0 | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | ($24.00M) | - | - | - | - | - | - |
Ratios
| Metric | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 96.4% | - | - | - | 69.4% | 96.3% | 95.9% | - | 89.5% |
| Operating margin | - | -527.5% | -430.3% | - | - | -655.3% | -490.8% | -816.3% | - | -719.0% |
| EBITDA margin | - | - | - | - | - | - | - | -813.6% | - | - |
| Net margin | - | -561.9% | -445.7% | - | - | -673.7% | -534.9% | -847.1% | - | -731.3% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | 1.05 | - | - | - | - | - | - |
| R&D / Revenue | - | 454.0% | 417.9% | - | - | 551.6% | 415.4% | 657.3% | - | 595.8% |
| SG&A / Revenue | - | 170.0% | 119.2% | - | - | 173.1% | 171.8% | 254.9% | - | 165.4% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | - | -32.4% | -28.6% | -23.0% | - | -18.9% | -13.4% | -14.8% | - | -15.8% |
| Return on equity | - | 1124.1% | -135.3% | -64.7% | - | -34.6% | -21.3% | -23.3% | - | -24.8% |
| Return on invested capital | - | -34.2% | -28.4% | -23.4% | - | -17.7% | -11.2% | -14.8% | - | -14.6% |
| Liquidity | ||||||||||
| Current ratio | 0.71 | 3.31 | 4.22 | 4.04 | 4.68 | 5.45 | 7.22 | 4.02 | 3.46 | 4.50 |
| Quick ratio | 0.68 | 3.24 | 4.15 | 3.82 | 4.57 | 5.34 | 7.09 | 3.97 | 3.37 | 4.38 |
| Cash ratio | 0.48 | 1.66 | 1.38 | 0.63 | 1.03 | 1.01 | 1.67 | 1.27 | 0.74 | 2.24 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | -25.40 | 2.64 | 1.13 | 0.72 | 0.50 | 0.38 | 0.20 | 0.33 | 0.32 |
| Debt / Assets | 0.00 | 0.73 | 0.56 | 0.40 | 0.33 | 0.27 | 0.24 | 0.13 | 0.19 | 0.20 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | -12.0x | -14.9x | -17.3x | - | -24.1x | -21.5x | -24.6x | - | -24.4x |
| Equity multiplier | -2.69 | -34.70 | 4.73 | 2.82 | 2.17 | 1.84 | 1.59 | 1.58 | 1.75 | 1.57 |
| Liabilities / Assets | 1.37 | 1.03 | 0.79 | 0.64 | 0.54 | 0.46 | 0.37 | 0.37 | 0.43 | 0.36 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.06 | 0.06 | - | - | 0.03 | 0.02 | 0.02 | - | 0.02 |
| Inventory turnover | - | 0.10 | - | 0.02 | - | 0.44 | 0.05 | 0.06 | - | 0.12 |
| Days sales outstanding | - | 150d | 292d | - | - | 223d | 93d | 312d | - | 332d |
| Days inventory outstanding | - | 3507d | - | 16512d | - | 835d | 6952d | 6338d | - | 3008d |
| Days payable outstanding | - | 15419d | - | 36679d | - | 3112d | 24039d | 30587d | - | 7751d |
| Cash conversion cycle | - | -11761d | - | - | - | -2054d | -16995d | -23937d | - | -4411d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -20.3% | 13.5% | - | - | 32.4% | 95.1% | -26.7% | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | 10.8% | - | - | - | 2.6% | 115.7% | -28.7% | - | - |
| Operating income growth (YoY) | - | 35.8% | 0.5% | -2.0% | - | -20.7% | -9.4% | -38.0% | - | -47.3% |
| Net income growth (YoY) | - | 33.5% | 5.4% | -0.6% | - | -22.0% | -14.1% | - | - | -41.7% |
| EPS growth (YoY) | - | 33.9% | 7.8% | 18.8% | - | - | 15.0% | -3.2% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | -85.1% | -63.8% | -23.6% | -12.5% | -5.7% | -22.9% | -23.8% | -3.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$18.17M totalProduct$15.52M · 85.4%
Autorisation Temporaire DUtlisation Member$2.40M · 13.2%
Other Revenue$250.0K · 1.4%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Eiger BioPharmaceuticals against the 5 most active filers in the same SIC group.